ZZZhiming Zhu

Zhiming Zhu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhiming Zhu has a total of 59 co-authors. Here are the top co-authors by number of shared publications:

  • Mei You

    Department of Hypertension and Endocrinology, Center for Hypertension and Metabolic Diseases, Chongqing Key Laboratory of Metabolic Vascular Diseases, Daping Hospital, Army Medical University, Chongqing Institute of Hypertension, Chongqing 400042, China

    4 shared publications
  • Qing Zhou

    Department of Hypertension and Endocrinology, Center for Hypertension and Metabolic Diseases, Chongqing Key Laboratory of Metabolic Vascular Diseases, Daping Hospital, Army Medical University, Chongqing Institute of Hypertension, Chongqing 400042, China

    4 shared publications
  • Fang Sun

    Department of Hypertension and Endocrinology, Daping Hospital, Center for Hypertension and Metabolic Diseases, Army Medical University of PLA, Chongqing Institute of Hypertension, Chongqing, People’s Republic of China

    3 shared publications
  • Hongbo He

    Department of Hypertension and Endocrinology, Center for Hypertension and Metabolic Diseases, Daping Hospital, Army Medical University, Chongqing Institute of Hypertension, Chongqing, China

    3 shared publications
  • Li Li

    Department of Hypertension and Endocrinology, Center for Hypertension and Metabolic Diseases, Chongqing Key Laboratory of Metabolic Vascular Diseases, Daping Hospital, Army Medical University, Chongqing Institute of Hypertension, Chongqing 400042, China

    3 shared publications
  • Lijuan Wang

    Department of Hypertension and Endocrinology, Center for Hypertension and Metabolic Diseases, Chongqing Key Laboratory of Metabolic Vascular Diseases, Daping Hospital, Army Medical University, Chongqing Institute of Hypertension, Chongqing 400042, China

    3 shared publications

Latest Publications

  • Open Access

    The role of arachidonic acid metabolites in the subtype classification and pathogenesis of primary aldosteronism

    by Mei You, Li Li, Xintao Tan, Xiaoli Liu, Lijuan Wang, Tingbing Cao, Bowen Wang, Min Liu, Yue Gao, Qing Zhou, et al.

  • Open Access

    Frailty progression before and after diabetes onset among older adults in china: a nationwide cohort study

    by Ruomei Yang, Fang Sun, Zongming Yang, Zhencheng Yan, Zhigang Zhao, Hongbo He, Zhiming Zhu

    Although epidemiological studies have established a link between diabetes and frailty, the dynamic changes in frailty before and after diabetes diagnosis r


  • Diagnostic performance of 24-hour urinary aldosterone for primary aldosteronism in patients with or without discontinuation of antihypertensive medications

    by Mei You, Xin Li, Huandong Zhao, Zhongping Bai, Yushuang Liu, Qing Zhou, Qiang Li, Ruomei Yang, Hexuan Zhang, Hongbo He, et al.

    Primary aldosteronism (PA) is the most common form of secondary hypertension. However, its diagnosis is complicated by the need to withdraw interfering antihypertensive medications. Traditionally, 24-h urinary aldosterone (Uald) level measurement is employed as part of the oral sodium loading test to diagnose PA. However, the diagnostic efficacy of 24-h Uald for PA under a usual diet and without drug washout remains unclear. This retrospective study enrolled 583 patients with essential hypertension (EH) and 259 patients with PA, as well as an external validation cohort comprising 157 hypertensive patients. Patients with unilateral PA presented higher 24-h Uald levels than those with bilateral PA. Combination antihypertensive therapy reduced 24-h Uald levels in both EH and PA groups. Receiver operating characteristic curve analysis revealed similar areas under the curve for 24-h Uald diagnosing PA between the off-medication group (0.879, 95% CI = 0.834–0.925) and the on-medication group (0.851, 95% CI = 0.817–0.886). The optimal 24-h Uald cut-offs for PA diagnosis were 9.57 μg (sensitivity 79.4%, specificity 88.6%) in the off-medication group and 8.41 μg (sensitivity 75.8%, specificity 79.4%) in the on-medication group, with closely matched thresholds observed between patients receiving renin-increasing medications (8.52 μg) and those on combined renin-increasing and renin-suppressing therapy (8.39 μg). The diagnostic accuracy of 24-h Uald reached 89.2% in the external validation cohort. Our research indicates that the 24-h Uald test is clinically feasible for diagnosing PA without additional sodium supplementation or drug washout. However, the diagnostic threshold for 24-h Uald should be adjusted downward in patients on medications.


  • Open Access

    Endothelial SIRT3 deficiency predisposes brown adipose tissue to whitening in diet-induced obesity

    by Qing Zhou, Zongshi Lu, Bowen Wang, Yuyan Wang, Li Li, Mei You, Lijuan Wang, Tingbing Cao, Dan Tong, Jie Xiang, et al.

    Endothelial dysfunction and vascular rarefaction are supposed to be secondary to metabolic diseases, while recent evidence has revealed the primary roles of endothelium in initiating and accelerating metabolic disorders. Here, the effects and underlying mechanisms of endothelial SIRT3 in modulating the whitening of BAT during obesity progression were explored. Therefore, mice with global or BAT regional endothelium-specific Sirt3 knockout were constructed and fed with high-fat diet (HFD). The results showed that both global and BAT regional endothelium-specific Sirt3 knockout accelerated diet-induced weight gain, accompanied by glucose intolerance, insulin resistance, and BAT whitening. In vitro results revealed that the inhibition or knockdown of endothelial Sirt3 impeded palmitic acid-induced angiogenesis deficiency, while the overexpression of Sirt3 exhibited the opposite effects. Furtherly, endothelial Sirt3 overexpression ameliorated palmitic acid-induced adipocyte dysfunction and proinflammatory macrophages polarization in a paracrine way. Mechanistically, endothelial SIRT3 deficiency increased the acetylation of fatty acid synthase (FASN), which disturbed the fatty acid metabolism and thus, leading to angiogenesis insufficiency. Moreover, loss of SIRT3 promoted adipocytes dysfunction and proinflammatory macrophage polarization via CASP1-mediated pyroptosis. Endothelial SIRT3 loss contributed to diet-induced BAT whitening and obesity progression and thus, could be a therapeutic target in treating obesity and associated metabolic diseases.


  • Open Access

    Gut microbiota alterations induced by Roux-en-Y gastric bypass result in glucose-lowering by enhancing intestinal glucose excretion

    by Zhigang Ke, Zongshi Lu, Fan Li, Qingyuan Zhao, Xianhong Jiang, Zhihao Hu, Fang Sun, Zongcheng He, Yi Tang, Qing Li, et al.

    Roux-en-Y gastric bypass (RYGB) results in glucose-lowering in patients with type 2 diabetes mellitus (T2DM) and may be associated with increased intestinal glucose excretion. However, the contribution of intestinal glucose excretion to glycemic control after RYGB and its underlying mechanisms are not fully elucidated. Here, we confirmed that intestinal glucose excretion significantly increased in obese rats after RYGB, which was negatively correlated with postoperative blood glucose levels. Moreover, we also found that the contribution of Biliopancreatic limb length, an important factor affecting glycemic control after RYGB, to the improvement of glucose metabolism after RYGB attributed to the enhancement of intestinal glucose excretion. Subsequently, we further determined through multiple animal models that intestinal glucose excretion is physiological rather than pathological and plays a crucial role in maintaining glucose homeostasis in the body. Finally, we employed germ-free mice colonized with fecal samples from patients and rats to demonstrate that enhanced intestinal glucose excretion after RYGB is directly modulated by the surgery-induced changes in the gut microbiota. These results indicated that the gut microbiota plays a direct causal role in the hypoglycemic effect of RYGB by promoting intestinal glucose excretion, which may provide new insights for developing gut microbiota-based therapies for T2DM.


  • Open Access

    Dietary apigenin ameliorates obesity-related hypertension through TRPV4-dependent vasorelaxation and TRPV4-independent adiponectin secretion

    by Aidi Mou, Fang Sun, Dan Tong, Lijuan Wang, Zongshi Lu, Tingbing Cao, Li Li, Mei You, Qing Zhou, Xiaorong Chen, et al.


  • Cracking the natriuresis puzzle: Insight from structural biology

    by Xiao Yu Tian, Wing Tak Wong, Zhiming Zhu


  • Open Access

    Nutritional Status in Chinese Patients with Obesity Following Sleeve Gastrectomy/Roux-en-Y Gastric Bypass: A Retrospective Multicenter Cohort Study

    by Chunlan Zhang, Xi Chen, Shiping Liu, Wei Liu, Dalong Zhu, Xiaoying Li, Shen Qu, Zhiming Zhu, Jingjing Zhang, Zhiguang Zhou

    Metabolic surgery (MS) is one of the most effective therapies for treating obesity. Due to the lack of multicenter cohort research on nutritional evaluations after surgery in Chinese patients, we explored the changes in nutritional status following MS in Chinese patients. This was a retrospective study of patients (n = 903) who underwent sleeve gastrectomy (SG) (n = 640) or Roux-en-Y gastric bypass (RYGB) (n = 263) for obesity at five different hospitals in China between 17 February 2011, and 20 December 2019. Major nutrients were evaluated at baseline and 1, 3, 6, and 12 months postoperatively. Hb levels decreased, and anemia prevalence increased at 12 months after MS in the premenopausal female group. Moreover, patients with preoperative anemia had an increased risk of postoperative anemia. The ferritin levels (p < 0.001) decreased and iron deficiency increased (p < 0.001) at 12 months after MS among premenopausal females. No significant changes in folate deficiency and vitamin B12 deficiency were found throughout the study. The bone mineral density (BMD) of the femoral neck, lumbar spine, and total hip significantly decreased from baseline to 12 months after MS; however, no new patients developed osteopenia or osteoporosis after MS. Based on 12 months of follow-up, premenopausal females presented a high incidence of anemia after MS. Although we found no differences in osteopenia and osteoporosis prevalence after MS, the BMD did decrease significantly, which suggests that nutrient supplements and long-term follow-up are especially necessary postoperation.